Annals of the rheumatic diseases · 2026
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aspari Maithri, Ong Voon, Søndergaard Klaus, Næser Esben, Hvid Malene, Ravnskjaer Kim, Tam Angela Y Y, Xu Shiwen, Bian Xinyue, Lopez Henry, Denton Christopher P, Abraham David, Deleuran Bent, Greisen Stinne R
Аннотация
OBJECTIVES: The study elucidates the impact of the programmed cell death protein 1 (PD-1) pathway on immune activation and fibrosis in diffuse cutaneous systemic sclerosis (dcSSc).
METHODS: We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo.
RESULTS: Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines.
CONCLUSIONS: Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.
METHODS: We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo.
RESULTS: Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines.
CONCLUSIONS: Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.